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Background.Despite increased knowledge about genetic aberra-
tions in pediatric T-cell acute lymphoblastic leukemia (T-ALL), no
clinically feasible treatment-stratifying marker exists at diagnosis.
Instead patients are enrolled in intensive induction therapies with
substantial side effects. In modern protocols, therapy response is
monitored by minimal residual disease (MRD) analysis and used
for postinduction risk group stratification. DNA methylation profil-
ing is a candidate for subtype discrimination at diagnosis and we
investigated its role as a prognostic marker in pediatric T-ALL. Pro-
cedure. Sixty-five diagnostic T-ALL samples from Nordic pediatric
patients treated according to the Nordic Society of Pediatric Hema-
tology and Oncology ALL 2008 (NOPHO ALL 2008) protocol were
analyzed by HumMeth450K genome wide DNA methylation arrays.
Methylation status was analyzed in relation to clinical data and early
T-cell precursor (ETP) phenotype. Results. Two distinct CpG island
methylator phenotype (CIMP) groups were identified. Patients with
a CIMP-negative profile had an inferior response to treatment com-
pared to CIMP-positive patients (3-year cumulative incidence of re-
lapse (CIR3y) rate: 29% vs. 6%, P = 0.01). Most importantly, CIMP
classification at diagnosis allowed subgrouping of high-risk T-ALL
patients (MRD 0.1% at day 29) into two groups with significant
differences in outcome (CIR3y rates: CIMP negative 50% vs. CIMP
positive 12%; P = 0.02). These groups did not differ regarding ETP
phenotype, but the CIMP-negative group was younger (P= 0.02) and
had higher white blood cell count at diagnosis (P= 0.004) compared
with the CIMP-positive group. Conclusions. CIMP classification at
diagnosis in combination with MRD during induction therapy is a
strong candidate for further risk classification and could confer im-
portant information in treatment decision making. Pediatr Blood
Cancer 2016;63:1185–1192. C© 2016 The Authors. Pediatric Blood &
Cancer, published by Wiley Periodicals, Inc.
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INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) accounts for
10–15% of childhood ALL, but is more common among ado-
lescents and adults.[1] The malignant transformation involves
several genomic changes altering the normal control of T-cell de-
velopment and proliferation.[2] Although the pathogenesis of T-
ALL has been extensively studied, few clinically useful prognos-
tic markers exist beyond minimal residual disease (MRD) status
during the first months of therapy.[3]
During the last decade, “epigenetics”(that is, functionally rel-
evant changes in the genome that might influence gene expres-
sion without affecting the nucleotide sequence), has emerged as
an important player in tumor development. One general find-
ing during malignant transformation is a decrease in global
DNA methylation, contributing to genomic instability, and an
increase in promoter associated CpG island methylation asso-
ciated with downregulation of tumor suppressor genes.[4] We
and others have demonstrated both subtype classification and
prognostic relevance of aberrant DNA methylation patterns
in various hematological disorders.[5–9] However, the defini-
tion of methylation classification into CpG island methylator
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phenotype (CIMP) subgroups is poorly defined and ranges
from classification of single predefined genes to unsupervised
genome-wide methylation profiling in different studies.[10] A
few other papers have been published on pediatric T-ALL,
methylation, and prognosis, but these studies have classified
CIMP status based on single selected genes and are not com-
parable with our genome-wide approach.[11,12]
Based on our previous finding of a strong prognostic sig-
nificance of promoter-associated DNA methylation in Swedish
T-ALL patients treated according to the Nordic Society of Pe-
diatric Hematology and Oncology (NOPHO) ALL 1992/2000
protocols,[6] we here explore its prognostic relevance in a new
independent Nordic cohort of patients treated with the cur-
rently usedNOPHOALL 2008 protocol. In contrast to theALL
1992/2000 protocols, the ALL 2008 protocol uses postinduction
MRD levels for risk group stratification.[1]
METHODS
T-Cell Acute Leukemia and Control Samples
Between July 2008 and March 2013, 113 children (age <18
years) were diagnosed in the Nordic countries with T-ALL and
treated according to the common NOPHO ALL 2008 proto-
col.[1] Sixty-five diagnostic bone marrow/peripheral blood sam-
ples were available in the NOPHO leukemia biobank in Up-
psala, Sweden, and were analyzed for methylation status. The
T-ALL diagnosis was in each case based on morphology and
flow cytometric immunophenotyping. Cytogenetic aberrations
were explored by G-band karyotyping and targeted FISH anal-
ysis.[1] Clinical data including white blood cell (WBC) count,
immunophenotype, cytogenetic aberrations at diagnosis, and
MRD status at treatment day 29 (end of induction) were evalu-
ated in relation to methylation status at diagnosis. MRD was
monitored by PCR and/or flow cytometry. PCR analysis of
clonal gene rearrangements was recommended for MRD quan-
tification in T-cell ALL and suchMRDdata [13] were usedwhen
available (n = 41). However, if no PCR-based MRD was avail-
able, flow cytometric quantification of MRD [14] was used (n =
20). Four cases lacked both PCR and flowMRD data and were
excluded from the survival analyses that included MRD.
T-cell maturation stage was evaluated in the diagnostic sam-
ples. The European Group for the Immunological Classifica-
tion of Leukemias (EGIL) criteria were used as defined by
Bene et al.[3] The immature subgroup of T-ALL described by
Coustan-Smith et al. [15] as “early T-cell precursor” (ETP) is
characterized by hematopoietic stem cell (HSC) and myeloid
progenitor markers.[3,15–17]
Publicly available methylation data (NCBI GEO database,
GSE49618) of sorted T-cells (CD3+) and HSCs (CD34+,
CD38–) from healthy donors were used as reference samples in
themethylation heatmap (Fig. 1A) to illustratemethylation pro-
files of normal immature and mature hematopoietic cells.
The study was approved by the regional and/or national
ethics committees, and the patients and/or their guardians pro-
vided informed consent in accordance with the Declaration of
Helsinki.
Genome Wide CpG Site Methylation Profiling
DNA was extracted by the AllPrep DNA/RNA kit (Qiagen,
Hilden, Germany) and diagnostic T-ALL samples were ana-
Fig. 1. CIMP classification of T-ALL samples. (A)Heat map show-
ing 1,293 CpG sites in the CIMP panel for the 65 diagnostic T-ALL
samples and sorted normal CD34+/CD38– and CD3+ cells. The
samples were CIMP classified based on the percentage of methy-
lated CpGs in the CIMP panel (40% CIMP negative and >40%
CIMPpositive; Supplementary Table SII). (B) Verification of CIMP
classification by a six gene HRM panel. The mean methylation per-
centage of the HRM-panel versus percentage of methylated CpGs
in 1,293 array-CIMP panel showed a high correlation (R2 = 0.87).
lyzed by the HumMeth450K methylation array (lllumina, San
Diego, CA) covering 485,577 CpG sites. Bisulfite conversion
was performed according to manufacturer’s manual (Zymo Re-
search, Irvine, CA) and array analysis including preprocessing
and normalization was performed as previously described.[18]
CpG probes that align to multiple loci in the genome or were
located less than 3 bp from a known single nucleotide polymor-
phism were excluded.[19] The fluorescence intensities were ex-
tracted using the Methylation Module (1.9.0) in the Genome
Studio software (V2011.1). The methylation level (β value) of
each CpG site ranged from 0 (no methylation) to 1 (complete
methylation). The quality of each individual array was evaluated
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TABLE I. Clinical Characteristics and Outcome in 113 T-ALL Cases
CIMP Analyzed Not analyzed Total
N = 65 N = 48 P-value N = 113
Gender male/female 43/22 35/13 ns 78/35
Median age (range, years) 7 (1–17) 7 (2–17) ns 7 (1–17)
Median WBC x 109/l (range) 150 (1.6–983) 67.1 (0.7–938) 0.03 98.3 (0.7–983)
MRD day 29 <0.1%/0.1%/NA 28/33/4 29/18/1 ns 57/51/5
pCIR3y (SE) 0.15 ± 0.05 0.13 ± 0.06 ns 0.15 ± 0.04
pOS3y (SE) 0.79 ± 0.05 0.79 ± 0.07 ns 0.79 ± 0.04
NA, not analyzed; ns, not significant; pCIR3y, 3-year cumulative incidence of relapse; pOS3y, 3-year overall survival rate; SE, standard
error.
with built-in controls. Two replicate samples were included to
assess interassay reproducibility (R2 = 0.97–0.99). The methy-
lation array data were deposited in the NCBI GEO database,
GSE69954. The normalized β values were used as measures of
methylation levels and downstream analysis of the data was per-
formed using R (v2.15.0).
All samples were CpG island methylator phenotype (CIMP)
classified according to the previously described CIMP panel [6]
using 1,293 CpG sites present in the HumMeth450K array. In
short, in order to identify T-ALL methylation subgroups, the
CIMP panel was defined as the most variable CpG sites in
the 27K array (Illumina) within diagnostic T-ALL samples. The
CpG sites within the CIMP panel were characterized by be-
ing located within CpG islands and associated with polycomb-
target genes.[6]
In order to standardize CIMP classification independent of
clustering, a cut-off level for “percentage of methylated CpGs
within CIMP panel” was defined for the CIMP subgroups. Di-
agnostic T-ALL samples with>40%methylatedCpG sites (each
CpG site was considered methylated if the beta value was >0.4)
in the CIMP panel (1293 CpGs) were classified as CIMP posi-
tive, whereas samples with40% methylated sites were denoted
CIMPnegative. The cut-off was set to reflect the previously iden-
tified clusters to be the most discriminating with respect to prog-
nosis.[6]
Verification of Methylation Array Data by
High-Resolution Melting Curve Analysis
High-resolution melting (HRM) assays were designed for a
selection of genes in 1,293 CpG site CIMP panel, represent-
ing CpG sites with distinct differences in methylation levels be-
tween CIMP subgroups in the array. The genes included KLF4,
TFAP2C, IGFBP3, WNT3A, GATA4, and EYA4. Each 25 μl
HRM reaction mix contained 1X Epitect HRM PCR Master-
mix (Qiagen), 0.75 μM of forward and reverse primers (Sup-
plementary Table SI), and 10 ng DNA template. The analysis
was run in a RotorGene instrument (Qiagen) as follows: 95°C
for 5 min, followed by 35 cycles of 95°C for 10 sec, 55°C for 30
sec, and 72°C for 20 sec. HRM was conducted by melting from
60 to 90°C, rising by 0.1° each step. A standard curve was pre-
pared by mixing 100% methylated DNA (M.SssI treated) in dif-
ferent ratios with DNA from mitogen (wheat germ agglutinin)
stimulated primary lymphoblast T-cell cultures P7/R2 (theoret-
ically 0% methylated mononuclear cells). The methylation level
of each gene region covered in the HRM assay was estimated
in relation to the standard curve, and a mean methylation level
(%) of the six-gene HRM panel was calculated. DNA was avail-
able from 63 of 65 array-analyzed T-ALL samples. Data were
analyzed using Rotor-Gene R© software v1.7 (Qiagen).
Statistical Analysis
The Statistical Package for the Social Sciences (SPSS Inc.,
Chicago, IL) software for Macintosh 22 was used for the sta-
tistical analyses. The chi-square/Fisher’s exact test was used to
compare differences between subgroups among categorical vari-
ables and the Mann–Whitney U test was used for continuous
variables. Estimates of 3-year cumulative incidence of relapse
(pCIR3yr) and overall survival (pOS3yr) rates were calculated us-
ing the Kaplan–Meier method and the subgroups listed in ta-
bles were compared using the log rank test. The significance
level used in all tests was 0.05. Time in first remission (CR1)
was defined as time (month) from diagnosis until first event. In
CIR analysis, relapse was the endpoint. In the overall survival
(OS) analysis, death from any cause was the endpoint.Moreover,
the cumulative incidence of death in remission (CIDCR1) was
compared between CIMP subgroups. The NOPHO leukemia
registry is updated annually, and follow-up data were extracted
from the registry as of May 2015.
RESULTS
Demographic Data
One hundred thirteen children (age 18 years) were diag-
nosed with T-ALL in the Nordic countries between July 2008
andMarch 2013, and treated according to the Nordic study pro-
tocol NOPHO ALL 2008. Clinical response to induction ther-
apy with dexamethasone, vincristine, doxorubicin, and intrathe-
cal methotrexate [1] was evaluated by MRD at day 29. The re-
sponse to induction therapy determined whether the patients
were assigned to antimetabolite-based intermediate risk therapy
(MRD < 0.1%) or intensive myelosuppressive high risk (MRD
0.1%) block therapy, respectively.[1,20]
A total of 65 diagnostic T-ALL samples in the NOPHO
biobank were available for methylation analysis. Apart from
higher WBC counts at diagnosis for those included (P = 0.03),
there were no significant differences between the analyzed (n =
65) and not analyzed (n= 48) samples; that is, no statistically sig-
nificant differences were found regarding age, gender, or MRD
day 29 status (fraction <0.1%/0.1%; Table I). CIR and OS
analysis confirmed that the 65 patients with available samples
in the NOPHO biobank were representative for all pediatric T-
ALL cases diagnosed in the Nordic countries during the study
period with no difference in pCIR3yr between patients analyzed
Pediatr Blood Cancer DOI 10.1002/pbc
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TABLE II. Clinical Characteristics and Outcome in 65 CIMP Classified T-ALL
CIMP+ CIMP– Total
N = 40 N = 25 P-value N = 65
Gender male/female 27/13 16/9 ns 43/22
Median age (range, years) 7 (2–17) 8 (1–15) ns 7 (1–17)
Median WBC x 109/l (range) 77.1 (1.6–825) 228 (6.9–983) 0.03 150 (1.6–983)
MRD day 29 <0.1%/0.1%/NA 18/18/4 10/15/0 ns 28/33/4
ETP phenotype1 Yes/No/NA 6/28/6 2/20/3 ns 8/48/9
EGIL class2 Immature/cortical /mature/NA 13/19/2/6 7/11/4/3 ns 20/30/6/9
Follow-up status CR1 (median follow up; range, months) 35 (50; 2–76) 17 (58; 24–73) 52 (52; 2–76)
Relapse (median time to relapse, months) 2 (18) 7 (13) 9 (13)
DCR1 2 1 3
Induction failure 1 0 1
Resistant disease 0 0 0
Dead/alive 5/35 8/17 13/52
pCIR3y (SE) 0.06 ± 0.04 0.29 ± 0.09 0.01 0.15 ± 0.05
pCIDCR13y (SE) 0.05 ± 0.04 0.05 ± 0.05 ns 0.05 ± 0.03
pOS3y (SE) 0.87 ± 0.06 0.68 ± 0.1 0.08 0.79 ± 0.05
1Ref. [15]. 2Ref. [3]. NA, not analyzed; ns, not significant; CR1, first complete remission; DCR1, dead in CR1; SE, standard error; pCIR3y,
3-year cumulative incidence of relapse; pCIDCR13y, 3-year cumulative incidence of death in CR1; pOS3y, 3-year overall survival rate.
for methylation (n = 65) or not analyzed (n = 48, 15% vs. 13%,
P = 0.82) or pOS3yr (79% vs. 79%, P = 0.85; Table I).
CIMP Classification and Verification
The diagnostic T-ALL samples were analyzed by Hum-
Meth450K arrays, and CpG island methylation phenotype
(CIMP) classified by a previously defined panel of 1,293 CpG
sites.[6] Twenty-five T-ALL patients were classified as CIMP
negative and 40 were classified as CIMP positive (Fig. 1A and
Supplementary Table SII). The CIMP-negative samples had a
methylation profile very similar to normal CD3+ T-cells and
CD34+ HSCs (Fig. 1A and Supplementary Table SII).
The validity of the methylation arrays was determined by
HRM analysis of six gene regions covering a selection of CpG
sites with distinct differences in methylation levels between
CIMP subgroups in the array CIMP panel. The mean HRM
methylation level (%) of the six-gene HRM-CIMP panel cor-
related well with the percentage of methylated CpG sites in the
array-CIMP panel (R2 = 0.87, Fig. 1B).
CIMP Classes and Clinical Characteristics Including
T-Cell Maturation Stage
CIMP-negative (n= 25) and CIMP-positive (n= 40) T-ALL
patients showed no significant differences regarding gender, age,
or MRD status (<0.1%/0.1%) at day 29, but higher WBC val-
ues were found in CIMP-negative compared to CIMP-positive
cases (median WBC: 228 vs. 77 × 109/l; P = 0.03) (Table II).
Among the 65 methylation analyzed patients, 56 had suf-
ficient data to allow for T-cell maturation stage classification
(EGIL class and ETP phenotype). We found no significant
association between T-cell maturation stage (EGIL class or ETP
phenotype) and CIMP class (Table II).
Survival Analysis
The pCIR3yr analysis of patients classified according to
CIMP status showed significant differences (P = 0.01) with the
best prognosis for CIMP-positive cases (pCIR3yr 6%) compared
to CIMP-negative cases (pCIR3yr 29%) (Fig. 2A and Table II).
The pOS3yr also differed between the CIMP groups (pOS3yr: 87%
for CIMP positive and 68% for CIMP negative), but was not
significant (P = 0.08) (Fig. 2A and Table II). The cumulative
incidence of death in remission (pCIDCR13yr) did not differ be-
tween CIMP subgroups (P = 0.86) (Table II) and was therefore
not corrected for.
MRD at day 29 is used for risk group stratification in the
current NOPHO ALL 2008 protocol. The pCIR3yr and pOS3yr
analysis of the 61 samples with availableMRDdata showed that
MRD 0.1% day 29 identified individuals with poor outcome
(pCIR3yr MRD 0.1%, 30% and MRD <0.1%, 0%, P = 0.003,
and pOS3yr MRD 0.1%, 65% and MRD <0.1%, 100%, P =
0.001; Fig. 2B).
By combining CIMP status at diagnosis and MRD level at
day 29, this prognostic information was enhanced (P < 0.001;
Fig. 2C). TheMRD0.1%/CIMPnegative group could be iden-
tified as a group with very poor prognosis (pCIR3yr 50% and
pOS3yr 45%), whereas theMRD0.1%/CIMP-positive patients
had amuch better outcome (pCIR3yr 12% and pOS3yr 83%) (P=
0.02 [CIR], P= 0.03 [OS]; Table III). Interestingly, CIMP status
did not play a role for patients with low MRD, since there were
no events in the MRD <0.1% group, irrespective of the CIMP
status (pCIR3yr 100% and pOS3yr 100%) (Fig. 2C and Table III).
When comparing the MRD 0.1%/CIMP negative group
with the MRD 0.1%/CIMP positive group for clinical data
including age, gender, WBC at diagnosis, ETP, and EGIL
status, only age and WBC differed significantly. Thus, the
MRD 0.1%/CIMP negative group had higher WBC count
(Median: 241 × 109/l vs. 72 × 109/l, P = 0.004) and were
younger (Median: 7.0 vs. 11.5 years, P = 0.02) at diagno-
sis compared with the MRD 0.1%/CIMP positive group
(Table III).
To further study their relation, WBC were plotted together
with CIMP and MRD status (Fig. 3) showing that our identi-
fied poor prognostic, MRD 0.1%/CIMP negative group, was
characterized by high WBC counts at diagnosis.
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Fig. 2. Survival analysis based on CIMP classification andMRD level at day 29. Overall survival (OS) and cumulative incidence of relapse
(CIR) in (A) CIMP subgroups, CIMP negative (n= 25), and CIMP positive (n= 40). (B)MRD0.1% (n= 33) andMRD<0.1% (n= 28)
subgroups at day 29. (C) CIMP+/MRD 0.1% (n = 18), CIMP+/MRD <0.1% (n = 18), CIMP–/MRD 0.1% (n = 15), CIMP–/MRD
<0.1% (n = 10) subgroups.
Pediatr Blood Cancer DOI 10.1002/pbc
1190 Borssén et al.
TABLE III. Clinical Characteristics, Outcome, and Therapy Stratification in 61 T-ALL in CIMP/MRD Subgroups
MRD  0.1% MRD < 0.1%
CIMP+ (N = 18) CIMP– (N = 15) P-value CIMP+ (N = 18) CIMP– (N = 10) P-value
Gender male/female 13/5 10/5 ns 12/6 6/4 ns
Median age (range, years) 11.5 (2–17) 7 (1–15) 0.02 5 (2–14) 12 (1–15) ns
Median WBC x 109/l
(range)
72 (3–560) 241 (52–983) 0.004 74 (4–825) 126 (7–492) ns
ETP1 Yes/no/NA 3/14/1 1/13/1 ns 2/11/5 1/7/2 ns
EGIL2 Immature/cortical /mature/NA 6/9/2/1 4/8/2/1 ns 5/8/0/5 3/3/2/2 ns
Therapy stratification after
day 29
Standard risk 0 0 0 0
Intermediate risk 0 0 17 9
High-risk chemo 16 13 1 1
High-risk SCTCR1 2 2 0 0
Follow-up status CR1 15 7 18 10
Induction failure 0 0 0 0
Resistant disease 0 0 0 0
Relapse 2 7 0 0
DCR1 1 1 0 0
Dead/alive 3/15 8/7 0/18 0/10
pCIR3y (SE) 0.12 ± 0.08 0.50 ± 0.14 0.02 0 0 ns
pOS3y (SE) 0.83 ± 0.09 0.45 ± 0.13 0.03 1 1 ns
1Ref. [15]. 2Ref. [3]. NA, not analyzed; SCTCR1, stem cell transplantation in CR1; pCIR3y, 3-year cumulative incidence of relapse; pOS3y,
3-year overall survival rate; SE, standard error.
Fig. 3. CIMP status, white blood cell count, and MRD level. Percentage of methylated CpGs in the CIMP panel versus log WBC count
at diagnosis in MRD < 0.1% and MRD 0.1% samples at day 29. CIMP status (40% or >40% methylated CpGs in CIMP panel) and
WBC at 100 × 109/l and 200 × 109/l are separated with lines in the figure; relapses are marked with filled circles.
DISCUSSION
Even though the outcome of pediatric T-ALL has improved
significantly over the last decades, the high intensive chemother-
apy treatment currently used may cause short- or long-term ad-
verse effects. Furthermore, the cure rate of relapsed T-ALL has
remained dismal, calling for improved risk stratification that
allow those with the highest risk of relapse to be allocated to
novel treatment strategies and/or HSC transplantation in first
remission.
We have previously shown a strong prognostic impact of
DNA methylation classification into CIMP groups in pedi-
atric T-ALL patients treated according to the NOPHO ALL
1992/2000 protocols.[6] However, in those protocols the cure
rate for T-cell ALL was generally poor. The present study in
an independent Nordic cohort confirms that CIMP classifi-
cation is a relevant clinical prognostic factor for childhood
T-ALL, also in the setting of contemporary treatment pro-
grams that integrate MRD measurements in the risk group al-
location. Although the overall pCIR rate has been improved
with the current ALL2008 protocol, CIMP status at diag-
nosis was a significant prognostic factor. Of special impor-
tance is that a combination of CIMP status at diagnosis and
MRD status at treatment day 29 could further identify pa-
tients with significantly different clinical outcomes. In the cur-
rent NOPHO ALL 2008 protocol (NCT00816049) for T-ALL,
MRD levels >0.1% at day 29 stratifies patients to an inten-
sified treatment schedule.[1] Whether a future combination of
CIMP classification and postinduction MRD levels will allow
down grading of CIMP-positive T-ALL patients to less inten-
sive chemotherapy must be evaluated in prospective trials. Im-
portantly, the prognosis for CIMP negative/MRD 0.1% pa-
tients is so dismal that novel treatment approaches are needed.
Methylation status does not seem to influence the initial re-
sponse to therapy since there were no significant difference in
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remaining leukemic cells after induction therapy (MRD sta-
tus day 29) in CIMP subgroups. The vast majority of leukemic
cells were eliminated by therapy regardless of methylation sta-
tus. However, the relapse frequency was higher in the CIMP-
negative leukemias. The reason for this we can only specu-
late upon but it might reflect different efficiency of eliminating
leukemic initiating cells in CIMP-positive and CIMP-negative
leukemias.
Our CIMP profile reflecting 1,293 CpGs is based on methy-
lation array analysis, and is a robust and informative, but yet
relatively expensive ( 350 USD/sample) and time consuming
technique (3 days). As an alternative technique for CIMP clas-
sification and to confirm the array CIMP classification, we used
HRManalysis based on six gene regions selected from theCIMP
panel to represent CpG sites with distinct differences in methy-
lation levels between the CIMP subgroups. The HRM classifi-
cation correlated well with the array-based CIMP classification,
and it can be run on single samples and be completed within 1
day. Therefore, HRM CIMP classification is an attractive alter-
native to array CIMP classification. However, the array analy-
sis has its advantage in gaining information about genome-wide
methylation patterns and can be used for additional analysis, in-
cluding copy number alterations.[21]
Prognostic impact of DNA methylation signatures has also
been observed in other hematological malignancies, including
myelodysplasia, acute myeloid leukemia (AML), and BCP-
ALL, andmethylationmodifiers play a therapeutic role.[8,22,23]
The prognostic relevance of CIMP classification in pediatric T-
ALL shown in this paper confirms our previous finding in a
separate T-ALL cohort. However, there are conflicting results
of CIMP status and prognosis in pediatric T-ALL,[11,12] but
these studies used 14–20 predefined genes for methylation clas-
sification in contrast to our genome-wide array approach. In or-
der to gain the full potential of DNA methylation classification
as a prognostic marker in T-ALL, further validation of larger
cohorts is needed.
A deeper functional understanding of the complex role of
DNA methylation aberrations in the development and progres-
sion of hematological malignancies is still missing.
Genetic subtypes of childhood ALL and AML have been
associated with DNA methylation signatures.[24–26] A recent
study by Amabile et al. showed that in a murine chronic myeloid
leukemia (CML) model, induction of BCR-ABL could trig-
ger DNA methylation changes. Furthermore, it was shown that
aberrant DNA methylation had the potential to contribute to
leukemia progression in primary CML cells.[27]
Genome-wide methylation studies of the mouse hematopoi-
etic system identified specific signatures associated with lineage
commitment and T-cell maturation stage and showed that cells
committed to a myeloid lineage had lower global methylation
levels than cells committed to a lymphoid lineage.[28] Immature
T-ALL and ETP-ALL, with myeloid molecular characteristics,
have been associatedwith poor outcome.[15,29–32]However, we
found no significant association of CIMP subgroup with T-cell
maturation stage based on ETP phenotype or EGIL classifica-
tion.
TheMRD0.1%/CIMP negative group was associated with
high WBC counts at diagnosis. WBC count is not used as a
stratifier for therapy in T-ALL in the current protocol but anal-
ysis are ongoing whether or not it should be included in fu-
ture risk assessments.[33] The CIMP, MRD, and WBC fac-
tors partly covaried and it seems that combining two of these
three factors may be useful to further define different risk
groups. However, larger sample size is needed to study their rela-
tion/independence in detail by multivariate Cox regression anal-
ysis.
DNA methylation alterations have been shown to accumu-
late in cells over time,[18,34,35] and our recent publication on
a T-cell culture model for immortalization showed overlapping
methylation alterations in long-term cultured immortalized cell
cultures and CIMP-positive T-ALL.[18] Age-related alterations
in the DNA methylation patterns have been studied in the on-
togeny of HSCs showing a significant global DNA hypermethy-
lation in older HSCs. The same study found that hypermethyla-
tion occurred at polycomb repressive complex 2 (PRC2) target
loci upon forced proliferation of HSCs.[36] Our CIMP profile is
enriched for CpG sites located in polycomb target genes.[6] The
fact that the CIMP-negative subgroup showed a similar methy-
lation profile to normal CD3+ and CD34+/CD38– cells suggests
that these cases might have undergone fewer rounds of replica-
tions.
Recurring loss-of-function mutations and deletions have
been identified in the PRC2 components (EZH2, SUZ12, and
EED) in pediatric T-ALL.[32] In adult T-ALL, mutations in
RUNX1 and the DNA methyltransferase DNMT3A gene were
associated with poor prognosis.[37,38] Recently, DNMT3Amu-
tated preleukemic HSCs have been identified in AML that were
resistant to chemotherapy and persisted in remission, indicat-
ing that they might represent a reservoir from which relapse
arises.[39] It remains to be determined, if mutations or genetic
aberrations in DNA methylation associated genes or oncogenes
can be associated with CIMP subgroups.
To further gain insight into characteristics of CIMP-positive
and CIMP-negative cells, the next step will be to perform tran-
scriptome and genome sequence analysis of diagnostic and re-
lapse samples and relate to DNAmethylation and histone mod-
ification alterations. In vitro cytotoxicity analysis of CIMP-
positive and CIMP-negative cells will gain deepened knowledge
of drug resistance and cell signaling response in cells of different
methylation status.
To conclude, in this collaboration study between the Nordic
countries we show that DNA methylation patterns in diagnos-
tic T-ALL samples hold important prognostic information. Of
special interest was that CIMP status at diagnosis could separate
postinduction MRD-positive (>0.1%, day 29) patients into two
risk groups. Further dissection of the biology behind CIMP sta-
tus will hopefully result in the identification of novel therapeutic
targets.
ACKNOWLEDGMENTS
This study was supported by grants from the Swedish Can-
cer Society, the Swedish Research Council (Dnr 340-2013-5185),
the Swedish Childhood Cancer Foundation, the Medical Fac-
ulty of Umeå University, the Danish Childhood Cancer Foun-
dation, Lion’s CancerResearch Foundation (Umeå),Umeå Pae-
diatric Clinic Research Foundation, Magnus Bergvalls stiftelse,
and Uppsala-Umeå Comprehensive Cancer Consortium. Fi-
nancial support was provided through regional agreement be-
tween Umeå University and Västerbotten County Council on
Pediatr Blood Cancer DOI 10.1002/pbc
1192 Borssén et al.
cooperation in the field of medicine, odontology, and health.We
thank Helene Sandström for laboratory assistance.
Authors’ contributions
M. B., Z. H., M. Hu., G. R., E. F., and S. D. conceived and
designed the experiments; U. N. N., K. S., A. A˚., J. K., H. O.M.,
H. M., M. He. were involved in collection of data; S. D. and Z.
H. performed the experiments; M. B., Z. H., M. L., E. F., and S.
D. analyzed the data; and M. B., Z. H., K. S., G. R., and S. D.
wrote the paper with contribution from all coauthors.
REFERENCES
1. Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallbook H, Heyman M, HolmMS,
Hulegardh E, Klausen TW, Marquart HV, Jonsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen
M, Vaitkeviciene G, Vettenranta K, Asberg A, Schmiegelow K. Risk group assignment differs for
children and adults 1–45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008
protocol. Eur J Haematol 2013;90:404–412.
2. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin
Invest 2012;122:3398–3406.
3. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’tVeer MB. Proposals for
the immunological classification of acute leukemias. European Group for the Immunological Char-
acterization of Leukemias (EGIL). Leukemia 1995;9:1783–1786.
4. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148–1159.
5. Borssén M, Cullman I, Noren-Nystrom U, Sundstrom C, Porwit A, Forestier E, Roos G. hTERT
promoter methylation and telomere length in childhood acute lymphoblastic leukemia associations
with immunophenotype and cytogenetic subgroup. Exp Hematol 2011;39:1144–1151.
6. Borssén M, Palmqvist L, Karrman K, Abrahamsson J, Behrendtz M, Heldrup J, Forestier E, Roos
G, Degerman S. Promoter DNA methylation pattern identifies prognostic subgroups in childhood
T-cell acute lymphoblastic leukemia. PLoS One 2013;8:e65373.
7. Deneberg S, GrovdalM,KarimiM, JanssonM,NahiH, Corbacioglu A,Gaidzik V,DohnerK, Paul
C, Ekstrom TJ, Hellstrom-Lindberg E, Lehmann S. Gene-specific and global methylation patterns
predict outcome in patients with acute myeloid leukemia. Leukemia 2010;24:932–941.
8. Milani L, LundmarkA,KiialainenA,Nordlund J, Flaegstad T, Forestier E,HeymanM, Jonmunds-
son G, Kanerva J, Schmiegelow K, Soderhall S, Gustafsson MG, Lonnerholm G, Syvanen AC.
DNA methylation for subtype classification and prediction of treatment outcome in patients with
childhood acute lymphoblastic leukemia. Blood 2010;115:1214–1225.
9. Shen L, KantarjianH,GuoY, Lin E, Shan J, HuangX, BerryD, Ahmed S, ZhuW, Pierce S, Kondo
Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to
therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605–613.
10. Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovee JV, French PJ, van den Brandt
PA, Schouten LJ, de Meyer T, van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, van Enge-
land M. The CpG island methylator phenotype: What’s in a name? Cancer Res 2013;73:5858–5868.
11. Kraszewska MD, Dawidowska M, Larmonie NS, Kosmalska M, Sedek L, Szczepaniak M,
GrzeszczakW, Langerak AW, Szczepanski T,WittM, Polish Pediatric Leukemia Lymphoma Study
G. DNAmethylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as
compared with normal thymic subsets: Insights into CpG island methylator phenotype in T-ALL.
Leukemia 2012;26:367–371.
12. Takeuchi S, Matsushita M, Zimmermann M, Ikezoe T, Komatsu N, Seriu T, Schrappe M, Bar-
tram CR, Koeffler HP. Clinical significance of aberrant DNA methylation in childhood acute lym-
phoblastic leukemia. Leuk Res 2011;35:1345–1349.
13. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr
T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord
K, Raff T, van der Schoot CE, vanDongen JJ, European StudyGroup onMRDdiALL. Analysis of
minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time
quantitative PCR data. Leukemia 2007;21:604–611.
14. Bjorklund E, Matinlauri I, Tierens A, Axelsson S, Forestier E, Jacobsson S, Ahlberg AJ, Kauric G,
Mantymaa P, Osnes L, Penttila TL, Marquart H, Savolainen ER, Siitonen S, Torikka K, Mazur
J, Porwit A. Quality control of flow cytometry data analysis for evaluation of minimal residual
disease in bone marrow from acute leukemia patients during treatment. J Pediatr Hematol Oncol
2009;31:406–415.
15. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rub-
nitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D. Early T-cell precursor leukaemia:
A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10:147–156.
16. Chopra A, Bakhshi S, Pramanik SK, Pandey RM, Singh S, Gajendra S, Gogia A, Chandramohan
J, Sharma A, Kumar L, Seth R, Rai S, Kumar R. Immunophenotypic analysis of T-acute lym-
phoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL. Eur J Haematol
2014;92:211–218.
17. Hayhoe FG. Classification of acute leukaemias. Blood Rev 1988;2:186–193.
18. Degerman S, Landfors M, Siwicki JK, Revie J, Borssen M, Evelonn E, Forestier E, Chrzanowska
KH, Ryden P, Keith WN, Roos G. Immortalization of T-cells is accompanied by gradual changes
in CpG methylation resulting in a profile resembling a subset of T-cell leukemias. Neoplasia
2014;16:606–615.
19. Nordlund J, Backlin CL, Wahlberg P, Busche S, Berglund EC, Eloranta ML, Flaegstad T,
Forestier E, Frost BM, Harila-Saari A, Heyman M, Jonsson OG, Larsson R, Palle J, Ronnblom
L, Schmiegelow K, Sinnett D, Soderhall S, Pastinen T, Gustafsson MG et al. Genome-wide sig-
natures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol
2013;14:r105.
20. Frandsen TL, HeymanM,Abrahamsson J, VettenrantaK, Asberg A, VaitkevicieneG, Pruunsild K,
Toft N, Birgens H, Hallbook H, Quist-Paulsen P, Griskevicius L, Helt L, Hansen BV, Schmiegelow
K. Complying with the European Clinical Trials directive while surviving the administrative pres-
sure: An alternative approach to toxicity registration in a cancer trial. Eur J Cancer 2014;50:
251–259.
21. Feber A, Guilhamon P, Lechner M, Fenton T, Wilson GA, Thirlwell C, Morris TJ, Flanagan AM,
Teschendorff AE, Kelly JD, Beck S. Using high-density DNA methylation arrays to profile copy
number alterations. Genome Biol 2014;15:R30.
22. FigueroaME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth
J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Lowenberg B,
Delwel R, Melnick A. DNA methylation signatures identify biologically distinct subtypes in acute
myeloid leukemia. Cancer Cell 2010;17:13–27.
23. Griffiths EA, Gore SD. Epigenetic therapies in MDS and AML. Adv Exp Med Biol 2013;754:253–
283.
24. FigueroaME, Chen SC, Andersson AK, Phillips LA, Li Y, Sotzen J, KunduM, Downing JR, Mel-
nick A,Mullighan CG. Integrated genetic and epigenetic analysis of childhood acute lymphoblastic
leukemia. J Clin Invest 2013;123:3099–3111.
25. Nordlund J, Backlin CL, Zachariadis V, Cavelier L, Dahlberg J, Ofverholm I, BarbanyG,Nordgren
A, Overnas E, Abrahamsson J, Flaegstad T, Heyman MM, Jonsson OG, Kanerva J, Larsson R,
Palle J, SchmiegelowK, GustafssonMG, LonnerholmG, Forestier E et al. DNAmethylation-based
subtype prediction for pediatric acute lymphoblastic leukemia. Clin Epigenetics 2015;7:11.
26. Qu X, Davison J, Du L, Storer B, Stirewalt DL, Heimfeld S, Estey E, Appelbaum FR, Fang M.
Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid
leukemia. Epigenetics 2015;10:526–535.
27. Amabile G, Di Ruscio A, Muller F, Welner RS, Yang H, Ebralidze AK, Zhang H, Levantini E, Qi
L, Martinelli G, Brummelkamp T, Le BeauMM, Figueroa ME, Bock C, Tenen DG. Dissecting the
role of aberrant DNA methylation in human leukaemia. Nat Commun 2015;6:7091.
28. Ji H, Ehrlich LI, Seita J, Murakami P, Doi A, Lindau P, Lee H, Aryee MJ, Irizarry RA, Kim
K, Rossi DJ, Inlay MA, Serwold T, Karsunky H, Ho L, Daley GQ, Weissman IL, Feinberg AP.
Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature
2010;467:338–342.
29. Allen A, Sireci A, Colovai A, Pinkney K, Sulis M, Bhagat G, Alobeid B. Early T-cell precursor
leukemia/lymphoma in adults and children. Leuk Res 2013;37:1027–1034.
30. Haydu JE, FerrandoAA. Early T-cell precursor acute lymphoblastic leukaemia. CurrOpinHematol
2013;20:369–373.
31. Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, Jenkinson S, Hough R,
Vora A. Outcome for children and young people with Early T-cell precursor acute lymphoblastic
leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 2014;166:421–424.
32. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J,
Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov
A, Becksfort J, Gupta P et al. The genetic basis of early T-cell precursor acute lymphoblastic
leukaemia. Nature 2012;481:157–163.
33. Hastings C, Gaynon PS, Nachman JB, Sather HN, Lu X, Devidas M, Seibel NL. Increased
post-induction intensification improves outcome in children and adolescents with a markedly el-
evated white blood cell count (>/ = 200×10 /l) with T cell acute lymphoblastic leukaemia but
not B cell disease: a report from the Children’s Oncology Group. Br J Haematol 2015;168:533–
546.
34. Tommasi S, Zheng A, Weninger A, Bates SE, Li XA, Wu X, Hollstein M, Besaratinia A. Mam-
malian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic Acids
Res 2013;41:182–195.
35. Koch CM, Joussen S, Schellenberg A, Lin Q, Zenke M, Wagner W. Monitoring of cellular senes-
cence by DNA-methylation at specific CpG sites. Aging Cell 2012;11:366–369.
36. Beerman I, Bock C, Garrison BS, Smith ZD, Gu H,Meissner A, Rossi DJ. Proliferation-dependent
alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. Cell Stem
Cell 2013;12:413–425.
37. Grossmann V, Haferlach C, Weissmann S, Roller A, Schindela S, Poetzinger F, Stadler K, Bellos
F, Kern W, Haferlach T, Schnittger S, Kohlmann A. The molecular profile of adult T-cell acute
lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis
in T-ALL. Genes Chromosomes Cancer 2013;52:410–422.
38. Mok MM, Du L, Wang CQ, Tergaonkar V, Liu TC, Yin Kham SK, Sanda T, Yeoh AE, Osato M.
RUNX1 point mutations potentially identify a subset of early immature T-cell acute lymphoblastic
leukaemia that may originate from differentiated T-cells. Gene 2014;545:111–116.
39. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer
AD, Schuh AC, Yee KW, McLeod JL, Doedens M, Medeiros JJ, Marke R, Kim HJ, Lee K,
McPherson JD,Hudson TJ, ConsortiumHP-LGP, BrownAMet al. Identification of pre-leukaemic
haematopoietic stem cells in acute leukaemia. Nature, 2014;506:328–333.
Pediatr Blood Cancer DOI 10.1002/pbc
